Leadership Overview
Daiichi Sankyo has 10 executives leading key functions including strategy, finance, and operations.
Driven by innovation, Daiichi Sankyo is a global pharmaceutical leader dedicated to developing novel medicines and advanced drug delivery methods, serving patients across more than 30 countries with a commitment to improving health outcomes worldwide.
Driven by innovation, Daiichi Sankyo is a global pharmaceutical leader dedicated to developing novel medicines and advanced drug delivery methods, serving patients across more than 30 countries with a commitment to improving health outcomes worldwide.
Leadership Roles at Daiichi Sankyo
Joji Nakayama - Representative Director, President and Chief Executive Officer
Joji Nakayama, the Representative Director, President and Chief Executive Officer at Daiichi Sankyo, directs the company's overarching strategy and global operations. Nakayama guides the organization's mission to develop and deliver innovative medicines, ensuring alignment with patient needs and market demands across over 30 countries. This leadership role involves setting the strategic vision for pharmaceutical technology advancements and drug discovery pipelines. By fostering a culture of scientific excellence, Joji Nakayama drives the company's commitment to improving global health outcomes. The Chief Executive Officer's focus extends to optimizing resource allocation and ensuring sustainable growth for Daiichi Sankyo's diverse portfolio. Nakayama's executive oversight ensures the company remains at the forefront of pharmaceutical innovation, addressing critical unmet medical needs through advanced research and development initiatives.
Kazuki Mori - Chief of Staff To Chief Executive Officer
Kazuki Mori, the Chief of Staff To Chief Executive Officer at Daiichi Sankyo, provides direct support to the CEO in executing strategic priorities and operational initiatives. Mori manages key projects, facilitates executive communications, and ensures seamless coordination across different business units. This role is vital for translating the CEO's vision into actionable plans that drive Daiichi Sankyo's global operations and pharmaceutical innovation. By streamlining executive workflows, Kazuki Mori enhances organizational efficiency and responsiveness. The Chief of Staff's responsibilities include preparing strategic briefings and coordinating leadership meetings. Mori's support is critical for the CEO's effectiveness in guiding Daiichi Sankyo's mission to develop and deliver life-changing medicines. This position ensures strategic alignment and operational excellence across the company.
Hiroyuki Okuzawa - Chief Financial Officer
Hiroyuki Okuzawa, the Chief Financial Officer at Daiichi Sankyo, manages the company's financial health and strategic fiscal planning. Okuzawa oversees all financial operations, including budgeting, forecasting, and investment strategies, ensuring robust financial management across global markets. This critical role involves optimizing capital allocation to support Daiichi Sankyo's research and development initiatives and market expansion efforts. By providing financial insights, Hiroyuki Okuzawa enables informed decision-making for new drug development and commercialization. The Chief Financial Officer's responsibilities extend to managing investor relations and ensuring compliance with international financial regulations. Okuzawa's leadership ensures the financial stability required to pursue Daiichi Sankyo's mission of delivering innovative medicines to patients worldwide. This executive function is vital for sustaining the company's growth and its commitment to advancing global healthcare.
Koji Ogawa - Chief Financial Officer & Head, Global Corporate Planning & Management
Koji Ogawa, the Chief Financial Officer & Head, Global Corporate Planning & Management at Daiichi Sankyo, orchestrates the company's financial strategy and long-term corporate planning. Ogawa directs financial resource allocation and oversees the development of strategic initiatives that drive sustainable growth across international markets. This dual role ensures financial discipline is integrated with forward-looking corporate planning, supporting Daiichi Sankyo's mission to deliver innovative medicines. By managing global corporate planning, Koji Ogawa aligns business objectives with financial capabilities, optimizing operational efficiency. The Chief Financial Officer's purview includes financial risk management and capital investment decisions. Ogawa's leadership is essential for navigating the complex global pharmaceutical landscape and ensuring the company's continued success in serving patients worldwide. This executive function underpins Daiichi Sankyo's commitment to scientific advancement and patient well-being.
Chloe Stern - Manager, Chief Financial Officer Planning Department
Chloe Stern, the Manager, Chief Financial Officer Planning Department at Daiichi Sankyo, supports the strategic financial planning and analysis functions. Stern contributes to the development of financial models and forecasts, ensuring resource alignment with company objectives. This role is integral to providing data-driven insights that inform executive financial decisions and investment strategies. By managing departmental planning, Chloe Stern enhances the efficiency and accuracy of financial operations. The Manager's responsibilities include coordinating budget processes and performance tracking across various business units. Stern's contributions are vital for maintaining Daiichi Sankyo's financial health and supporting its mission to deliver innovative medicines. This position plays a key part in the company's commitment to fiscal responsibility and strategic growth in the global pharmaceutical market.
Hiroshi Sugiyama - President
Hiroshi Sugiyama, the President at Daiichi Sankyo, leads significant operational divisions and drives strategic growth initiatives. Sugiyama oversees key business units, ensuring their alignment with the company's broader mission of delivering innovative pharmaceutical solutions. This leadership position involves guiding market strategies and fostering operational excellence across various regions. By directing divisional operations, Hiroshi Sugiyama contributes to Daiichi Sankyo's global expansion and its commitment to patient care. The President's responsibilities include managing cross-functional teams and optimizing resource deployment for maximum impact. Sugiyama's executive guidance is essential for advancing the company's pipeline of new medicines and enhancing its market presence. This role supports Daiichi Sankyo's dedication to improving global health outcomes through scientific advancement.
Suthas Thongprasert - President
Suthas Thongprasert, the President at Daiichi Sankyo, directs critical regional operations and spearheads market-specific strategic development. Thongprasert oversees the execution of business plans within designated territories, ensuring Daiichi Sankyo's medicines reach patients effectively. This leadership role focuses on adapting global strategies to local market needs and regulatory environments. By managing regional operations, Suthas Thongprasert enhances the company's footprint and patient access to innovative treatments. The President's responsibilities include fostering partnerships and driving commercial success in key markets. Thongprasert's expertise is vital for expanding Daiichi Sankyo's reach and fulfilling its mission to improve global health. This executive function supports the company's commitment to scientific innovation and patient well-being worldwide.
Naoko Banker - Chief of Staff & Senior Director, Pharmaceutical Technology
Naoko Banker, the Chief of Staff & Senior Director, Pharmaceutical Technology at Daiichi Sankyo, spearheads advancements in drug formulation and delivery systems. Banker directs the strategic implementation of cutting-edge pharmaceutical technologies, enhancing the efficacy and accessibility of medicines. This role involves close collaboration with research and development teams to translate scientific discoveries into viable therapeutic solutions. By overseeing technological integration, Naoko Banker ensures Daiichi Sankyo maintains its competitive edge in pharmaceutical innovation. The Chief of Staff's responsibilities include streamlining operational processes and supporting executive leadership in strategic decision-making. Banker's expertise in pharmaceutical technology is crucial for developing next-generation treatments that address significant patient needs globally. This position drives operational excellence and supports the company's mission to improve health outcomes through advanced science.
Kosuke Itagaki - Chief of Staff & Global System Owner
Kosuke Itagaki, the Chief of Staff & Global System Owner at Daiichi Sankyo, manages critical enterprise systems and supports executive decision-making. Itagaki oversees the implementation and maintenance of global IT infrastructure, ensuring operational continuity and data integrity across all business functions. This role is pivotal in harmonizing technological resources to support Daiichi Sankyo's strategic objectives in drug development and patient service. By acting as the Global System Owner, Kosuke Itagaki ensures that technological platforms effectively support the company's mission. The Chief of Staff's responsibilities include facilitating communication and coordination among various departments. Itagaki's leadership ensures that Daiichi Sankyo leverages technology efficiently to advance its global pharmaceutical operations and patient care initiatives. This executive function is key to maintaining operational excellence and driving innovation.
Caitlin Barnabo - Global Oncology Medical Affairs Chief of Staff
Caitlin Barnabo, the Global Oncology Medical Affairs Chief of Staff at Daiichi Sankyo, supports strategic initiatives within the oncology therapeutic area. Barnabo facilitates cross-functional collaboration among medical affairs, research, and commercial teams to advance oncology drug development and patient support programs. This role is crucial for ensuring the effective execution of medical strategies aimed at addressing critical cancer needs globally. By coordinating efforts, Caitlin Barnabo enhances the impact of Daiichi Sankyo's oncology portfolio. The Chief of Staff's responsibilities include managing key projects and communications within the medical affairs division. Barnabo's leadership is instrumental in driving Daiichi Sankyo's commitment to providing innovative treatments for cancer patients worldwide. This position supports the company's mission to improve health outcomes through specialized therapeutic advancements.
Explore Leadership Teams in Manufacturing
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Company Leadership MT
TK
Zydus is a global pharmaceutical company headquartered in Ahmedabad, India. Founded in 1952, the company operates manufacturing sites and research facilities across multiple states in India as well as in the United States and Brazil. Zydus specializes in developing, manufacturing, and distributing pharmaceutical products with a significant global footprint. The company maintains a strong presence in regulated markets including the United States, Europe, Latin America, and South Africa, while also serving numerous emerging markets worldwide. Zydus offers a comprehensive portfolio of pharmaceutical products and services, supported by extensive research and development capabilities.
Company Leadership HW
RR
HS
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Company Leadership
PC
AB
Asymchem Inc. is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to serving global pharmaceutical companies. They specialize in innovative green solutions as well as advanced drug development and manufacturing services. Their target clients primarily consist of pharmaceutical companies requiring comprehensive support in the areas of drug production and development. Asymchem's commitment to sustainability and development positions it as a preferred partner in the pharmaceutical sector.
Company Leadership HH
AK
EH
Frequently Asked Questions Regarding Daiichi Sankyo Top Executives and Leadership Team
